How long does hormone therapy take to work? What to expect in the first few months

It is probably the most repeated question among women who have just started hormone therapy: when will I notice something? The short, verified answer is that relief of menopausal symptoms with transdermal oestradiol appears during the first few weeks of treatment, according to the product information authorised in Spain itself, and that clinical guidelines set a first review at 3 months to assess whether it is working and whether it is being tolerated. The long answer includes an important nuance: there is no reliable week-by-week, symptom-by-symptom calendar. Anyone selling you that level of detail is filling in gaps that the evidence has not filled.

What the Spanish product information actually says

When a medicine is authorised in Spain, the AEMPS publishes its summary of product characteristics: the legal document setting out what it does, what it is approved for and what has been observed. The one for the oestradiol patch is sober on this point and says that relief of menopausal symptoms appears during the first few weeks of treatment. No specific day, no weekly percentage. That vagueness is not an oversight: it reflects the fact that individual response varies a great deal.

The mechanism, on the other hand, is clear. Oestradiol replaces the loss of oestrogen production in menopausal women and thereby relieves the symptoms associated with oestrogen deficiency. The Spanish product information places within that group vasomotor symptoms (hot flushes and night sweats), urogenital atrophy, sleep disturbance, mood changes, asthenia and bone loss. The fact that they all share a cause does not mean they all respond at the same pace, and that is precisely where the sources stop giving figures.

Three months: the standard window for knowing whether it works

If there is one timescale that recurs in the evidence, it is this one. NICE NG23, the British menopause management guideline, recommends reviewing each hormone treatment at 3 months to assess efficacy and tolerability, and annually thereafter unless the clinical situation suggests otherwise. The figure is not arbitrary: the landmark systematic review of oral oestrogens and hot flushes included only randomised double-blind trials lasting a minimum of 3 months (range from 3 months to 3 years, 21 trials and 2,511 participants). In other words, three months is the period that the research itself considered the minimum for measuring whether a hormone treatment works.

Translated into practice: noticing something in the first few weeks is what you would expect according to the product information, but the judgement about whether treatment is going well, whether the dose is right or whether tolerability is acceptable is made over months, not days. That review is also the point at which any adjustment is considered, because the Spanish product information sets out using the lowest effective dose for the shortest possible time and allows for reducing the oestradiol dose if tolerability is not satisfactory. None of this is decided at home: it is part of medical follow-up.

How much a hot flush actually improves

The size of the effect is well measured. In the systematic review by MacLennan and colleagues (Climacteric, 2001), oral hormone therapy reduced the weekly frequency of hot flushes by 77% compared with placebo, with a 95% confidence interval between 58.2% and 87.5%, and a weighted mean difference of −17.46 hot flushes per week (95% CI: −24.72 to −10.21). That wide interval, from 58 to 87%, is precisely an honest portrait of what happens in clinic: some women have a very marked response and others improve more modestly.

Along the same lines, the 2022 position statement of the North American Menopause Society holds that hormone therapy remains the most effective treatment for vasomotor symptoms and for the genitourinary syndrome of the menopause, and that it has been shown to prevent bone loss and fractures. If you want the full picture of who it is indicated for and what risks it carries, we set this out in the guide to menopausal hormone therapy and its real risks.

Why you will not find a week-by-week breakdown here

Highly detailed calendars circulate online: hot flushes in week 2, sleep in week 4, mood in week 8, brain fog in week 12. They sound reassuring and they are easy to share, but that level of granularity does not exist in the regulatory sources or in the guidelines. There are no verified data assigning a specific timescale to improvements in sleep, mood, joint pain or brain fog, nor any fixed timescales for the genitourinary syndrome. We would rather tell you that than invent it: a fake calendar only serves to make you feel like a failure if your body does not stick to it.

What does exist are indirect signals. In an observational cohort from a private clinic, all symptoms improved after 3 months of hormone therapy with or without testosterone, and the improvement was greatest for profound low mood (69%) and for anxiety and panic attacks (61%). It should be read with caution: it is a study without a control group, with testosterone added in some of the patients, which does not demonstrate causality and cannot simply be extrapolated to the general population. Even so, it suggests that mood symptoms also shift within that three-month window.

What can happen along the way and is to be expected

The first few months are not only about waiting for the benefit to arrive; they are also when the discomforts of adjusting show up. NICE NG23 notes that vaginal bleeding is a common adverse effect in women with a uterus during the first 6 months of systemic HRT and in the 3 months after any change of dose or preparation. That same bleeding, when it is unscheduled and appears beyond those timescales, should be reported promptly. The difference between what is expected and what needs looking at is, very often, a question of the calendar.

There is something else worth knowing about how treatment is structured: in women with an intact uterus, oestradiol must be combined with an appropriate progestogen, and oestrogen alone is reserved for women who have had a hysterectomy (except where endometriosis has been diagnosed). This is not a minor detail of the regimen, it is a safety condition set out in the Spanish product information, and it explains why the bleeding pattern in the first few months varies depending on the schedule. You can see how these combinations are organised today in the article on oestradiol and micronised progesterone in modern hormone therapy, and which discomforts are common at the start in the one on side effects in the first few weeks of hormone therapy.

On the subject of risks, the Spanish product information warns that both combined oestrogen-progestogen therapy and oestrogen-only therapy are associated with up to a 1.5-fold higher risk of ischaemic stroke; the relative risk does not vary with age or with time since menopause, but the absolute risk does increase with age. Anaphylactic or anaphylactoid reactions have also been reported post-marketing with oestradiol, at any point during treatment. And experience in women over 65 is limited. All of this is part of why starting hormone therapy is assessed individually and followed up over time.

When the benefits weigh more

The 2022 NAMS position statement argues that, for most healthy women under 60 and within 10 years of the onset of menopause, the benefits of hormone therapy outweigh the risks, with an emphasis on individualised treatment and periodic reassessment. That idea of reassessment connects with the point above: it is not a treatment decided once, but a decision that gets revisited. The Spanish product information expresses something similar when it states that HRT should be continued only for as long as the benefit outweighs the risk.

On bone protection, the verified figure is specific: doses of 1 to 2 mg a day of oestradiol generally prevent bone mineral loss, and higher doses are not usually used for that purpose. How long it takes to translate into measurable bone density is not something we can state with the available sources, so we do not.

What if I would rather try supplements first?

It is a fair question and the evidence has an answer, although less emphatic than the labels suggest. The Cochrane review of phytoestrogens concludes that there is no conclusive evidence that they effectively reduce the frequency or intensity of hot flushes and night sweats, although genistein concentrates merit further research. NICE acknowledges that there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms, but warns about the enormous variety of preparations and the uncertainty around their safety.

Unregulated hormone preparations deserve a chapter of their own, the ones sold as natural or compounded to order: NICE recommends explaining to women that their efficacy and safety are unknown, as are the quality and purity of their ingredients. If you are considering this route, the detailed review is in what works and what does not among phytoestrogens and supplements for the menopause.

In summary, and what you can do today

What you need to take away is simple: the first few weeks to start noticing something, three months to know whether it really works, and no reliable calendar more detailed than that. The rest is marketing. What does exist today in Spain is going through that process with support: menopause treatment with a prior assessment, prescription when appropriate by a registered doctor, and ongoing follow-up, which is exactly where the outcome is decided. If you are at the point of weighing it up, you can check whether you are eligible in a few minutes. It will also help to understand how menopause treatment by telemedicine works in Spain.